Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Embella
- Development stage
- Unknown
- Lead developer
- Espad Pharmed
- Administration
- Intradermal, Subcutaneous
01
Overview
Embella is a hyaluronic acid-based dermal filler developed and manufactured by Espad Pharmed for aesthetic and cosmetic procedures. It is indicated for soft-tissue augmentation, wrinkle correction, and facial volumization. Administered via dermal, subcutaneous, or intracutaneous injection, the product utilizes the physical and hygroscopic properties of cross-linked hyaluronic acid to provide immediate volume and hydration to the treated area. This mechanical filling effect smooths skin depressions and restores lost facial contours, offering a non-surgical solution for facial rejuvenation.
- Brand names
- Embella
Beyond the preview
Go deeper on Embella.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Embella.